Membrane Functionalized Nanoparticles for Ligand Screening
用于配体筛选的膜功能化纳米颗粒
基本信息
- 批准号:10325234
- 负责人:
- 金额:$ 24.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-15 至 2022-10-14
- 项目状态:已结题
- 来源:
- 关键词:AdsorptionAgonistAntibodiesAreaBeta ParticleBindingBinding ProteinsBiologicalBiological AssayBiomedical ResearchBiotinCaliberCarbohydratesCategoriesChelating AgentsChemicalsChemistryDepositionDetectionDevelopmentDiseaseElementsEnvironmentEnzyme Inhibitor DrugsEvaluationFeedbackG-Protein-Coupled ReceptorsG-substrateGovernmentHistidineHybridsIndustrializationInnovation CorpsInterviewIonsKnowledgeLabelLaboratory ResearchLegal patentLettersLigandsLiquid substanceMass Spectrum AnalysisMeasuresMembraneMembrane LipidsMembrane ProteinsMethodsMicroscopyModificationMolecularNanotechnologyNickelNicotinic ReceptorsOpticsOutcomePenetrationPhasePhospholipidsPlayPolymersPotassium ChannelPreparationPropertyProteinsRadiationRadioisotopesRadiometryReproducibilityResearchResearch PersonnelResearch Project GrantsRoleSamplingScintillation CountingSeriesSignal TransductionSilicon DioxideSmall Business Innovation Research GrantSodium ChlorideSolubilityStructureSurfaceTechniquesTechnologyThinnessTimeabsorptionaqueousbasebiomaterial compatibilitydetection assaydetection sensitivitydrug discoveryfluorophoreimaging modalityinnovationinterestnanomaterialsnanoparticlenovelparticlepreventprogramsprotein functionpublic health relevancereceptorreceptor bindingresearch clinical testingresponsescreeningsensorsmall moleculetool
项目摘要
Radioisotope (RI) labels remain a critical tool for drug discovery applications, particularly for measuring
analytes that are not detectable by traditional optical microscopy or electrochemical methods. Drug discovery
applications require minimal perturbation of the compounds of interest, preventing the use of large labels that
significantly change the structure and properties of the compounds, particularly for small molecules. RI labels
play a fundamental role in the high-sensitivity detection of compounds as diverse as small molecule enzyme
inhibitors, receptor agonists and antagonists, carbohydrates and carbohydrate derivatives, proteins, and many
others. RIs facilitate highly sensitive detection with minimal perturbation of the size and structure of the analyte,
compared to fluorescent labels, a particularly important property in drug discovery applications. RI labels provide
unparalleled sensitivity and precision for ligand-receptor binding assays, including G-protein coupled receptor
assays. Unfortunately, the low energy and short penetration depth of most common, biologically relevant RIs
also complicate detection, limiting the capabilities for this approach.
Scintillation Nanotechnologies, INC was founded in 2018 around a series of patent-pending, radioisotope-
responsive, hybrid nanomaterials. that overcome several key limitations associated with traditional radioisotope
counting methods. Scintillation Nanotechnologies has developed a novel nanomaterial, termed nanoSPA, for
sensitive detection of low-energy radioisotopes in intracellular environments. nanoSPA presents a number of
advantages compared to other methods for imaging small molecules, including a) enhanced compatibility with
aqueous samples; b) a high-surface area to volume (SA/V) ratio to enhance β-particle detection; c) an easily
modified surface for attachment of biomolecules and other chemical species; d) more reproducible surface
chemistry.
In this SBIR application, we propose to further develop nanoSPA with an emphasis on enhanced surface
functionalization using a diverse range of critically needed surface functionalities and to characterize the resulting
nanoSPA materials with respect to key quantitative criteria necessary to demonstrate the key commercial
potential of this platform. Once successfully developed, nanoSPA will provide an important new tool for
biomedical research.
放射性同位素(RI)标记仍然是药物发现应用的关键工具,特别是用于测量
传统光学显微镜或电化学方法检测不到的分析物。药物发现
应用需要对感兴趣的化合物进行最小的扰动,防止使用大的标记,
显著改变化合物的结构和性质,特别是对于小分子。RI标签
在高灵敏度检测小分子酶等多种化合物中发挥重要作用
抑制剂、受体激动剂和拮抗剂、碳水化合物和碳水化合物衍生物、蛋白质,以及许多
他人RI有利于高灵敏度检测,对分析物的大小和结构的干扰最小,
与荧光标记相比,荧光标记是药物发现应用中特别重要的性质。RI标签提供
配体-受体结合分析的无与伦比的灵敏度和精确度,包括G蛋白偶联受体
测定。不幸的是,大多数常见的生物学相关RI的低能量和短穿透深度
也使检测复杂化,限制了这种方法的能力。
闪烁纳米技术公司成立于2018年,围绕一系列正在申请专利的放射性同位素,
反应灵敏的混合纳米材料。它克服了传统放射性同位素的几个关键限制,
计数方法闪烁纳米技术公司开发了一种新的纳米材料,称为nanoSPA,
灵敏地检测细胞内环境中的低能放射性同位素。nanoSPA提供了许多
与用于成像小分子的其它方法相比的优点,包括a)增强的与
水性样品; B)高表面积与体积(SA/V)比,以增强β-颗粒检测; c)容易地
用于附着生物分子和其他化学物质的改性表面; d)更可再现的表面
化学.
在SBIR应用中,我们建议进一步开发nanoSPA,重点是增强表面
使用各种急需的表面官能度进行官能化,并表征所得的
nanoSPA材料的关键定量标准,以证明关键商业
这个平台的潜力。一旦开发成功,nanoSPA将为以下方面提供重要的新工具:
生物医学研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Colleen Janczak其他文献
Colleen Janczak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Colleen Janczak', 18)}}的其他基金
Nanomaterial Radioisotope Detectors for Intracellular Measurements
用于细胞内测量的纳米材料放射性同位素探测器
- 批准号:
10482292 - 财政年份:2022
- 资助金额:
$ 24.12万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 24.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 24.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 24.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)